Boston, MA -- (SBWIRE) -- 12/23/2013 -- Diabetic retinopathy is the principal cause of vision impairment in working-age adults throughout the world. A common microvascular complication of diabetes, diabetic retinopathy affects a third of diagnosed diabetics (Cheung et al., 2010). Clinically defined as an eye disease damaging the small blood vessels in the retina, diabetic retinopathy results from chronically high blood glucose levels in people with poorly-managed diabetes (Cheung et al., 2010; Fong et al., 2004; Kawasaki et al., 2011; Rubino et al., 2007).

According to the epidemiological literature, the duration of diabetes, hyperglycemia, hypertension, and dyslipidemia are all risk factors for the disease. Additionally, diabetic retinopathy has a comorbid relationship with various cardiovascular diseases. However, the causal pathway of this relationship has yet to be determined (Fong et al., 2004; Kawasaki et al., 2011; Klein et al., 2002).

According to GlobalData's forecast, the 7MM had 4,889,171 prevalent cases of diabetic retinopathy in 2012. The prevalent cases in the 7MM are expected to increase to 7,176,537 cases by 2022, at an Annual Growth Rate (AGR) of 4.68%. Japan had the largest proportion of prevalent cases in 2012 (61.21%, or 2,992,840 cases) of all the markets covered in this analysis.

View Full Report Details and Table of Contents

Scope

- The diabetic retinopathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic reitnopathy in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age, (over 40 years of age) and sex. The diagnosed prevalent cases are then further segmented by the grade of diabetic retinopathy (vision-threatening diabetic retinopathy [VTDR] and diabetic macular edema [DME]).
- The diabetic retinopathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to Get This Report

- Develop business strategies by understanding the trends shaping and driving the global diabetic retinopathy market.
- Quantify patient populations in the global diabetic retinopathy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic retinopathy therapeutics in each of the markets covered.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022
- EpiCast Report: Diabetic Foot Ulcers - Epidemiology Forecast to 2022
- EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
- EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022
- EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2022
- EpiCast Report: Hemophilia - Epidemiology Forecast to 2022
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- EpiCast Report: Breast Cancer - Epidemiology Forecast to 2022